3:46 PM
 | 
Feb 14, 2018
 |  BC Extra  |  Clinical News

Tetraphase falls on Phase III cUTI miss

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) lost $3.28 (60%) to $2.15 on Wednesday after reporting that IV eravacycline (TP-434) missed the co-primary endpoints in the Phase III IGNITE3 trial to treat complicated urinary tract infections (cUTIs). The company announced the news after market close on Tuesday.

On the 1,205-patient trial's co-primary...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >